Genflow Biosciences PLC Announces Mid-Year Operational and Corporate Summary
Rhea-AI Summary
Genflow Biosciences (LSE:GENF, OTCQB:GENFF) issued a mid-year update for the six months to 30 June 2026, highlighting clinical, partnership, IP and corporate progress for its SIRT6 longevity platform.
The SLAB dog trial reported positive preliminary interim results in February, with all treatment groups showing superior survival versus controls during dosing, no adverse events and a favourable safety and tolerability profile. Three‑month follow-up in April indicated maintained improvements and no adverse events, suggesting early durability; full methylation clock and muscle histology data are due after trial completion at end‑July 2026. The blinded GF‑1004 Dog Aging Study continues, with a six‑month efficacy assessment expected in July 2026.
Genflow entered a fully funded, non‑dilutive LNP collaboration with Acuitas Therapeutics, expanded confidentiality agreements with Tier‑1 animal health companies, and saw publication of an international PCT patent on SIRT6 variants for muscular diseases. The company also advanced glaucoma and broader sarcopenia programmes and appointed Gad Berdugo as Independent Non‑Executive Chairman.
Positive
- SLAB trial dogs: superior survival vs control, no adverse events
- Three‑month SLAB follow‑up showed maintained improvements with no adverse events
- GF‑1004 Dog Aging Study 180‑day blinded trial with six‑month readout due July 2026
- Acuitas collaboration fully funded and non‑dilutive for SIRT6 mRNA LNP delivery
- New PCT patent extends SIRT6 coverage into muscular disease indications
- New Chairman Gad Berdugo brings 30+ years of biotech leadership experience
Negative
- Acuitas collaboration not expected to have material impact on near‑term revenues
News Explained
The fully funded, non-dilutive Acuitas collaboration does not dilute ownership; Genflow’s SLAB trial remains incomplete pending its July 2026 endpoint update.
The
In practical terms, the release's “non-dilutive” label describes an arrangement that does not dilute ownership, while its funding term means Genflow owes no cash consideration.
Under the disclosed arrangement, Genflow supplies its SIRT6 mRNA payload, Acuitas formulates it using its LNP platform, and the formulations are returned for Genflow's preclinical evaluation; the release says Genflow expects no material near-term revenue impact. The SLAB dog trial is still ongoing: remaining methylation-clock and muscle-biopsy endpoints are in progress, and completion is expected at the end of
The next company-stated checkpoints are the comprehensive SLAB update after end-
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, UK / ACCESS Newswire / July 13, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), an emerging leader in the field of longevity research, provides a mid-year operational and corporate summary covering the six-month period to 30 June 2026.
No delays in the dog clinical trial: Positive preliminary interim results from the SLAB trial, followed by confirmation of sustained safety and efficacy at the three-month follow-up
Expansion of confidentiality agreements with additional Tier-1 animal health companies
Strategic technology collaboration with Acuitas Therapeutics ("Acuitas ") for fully funded, non-dilutive LNP delivery development
International patent publication extending SIRT6 protection into muscular disease indications
New Independent Non-Executive Chairman appointed, followed by two industry conference presentations
Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: "All development programmes are progressing on schedule without delays. The first half of 2026 has moved our SIRT6 platform from preclinical promise to a body of clinical, regulatory and commercial evidence. We reported positive interim data from SLAB, then confirmed at the three-month follow-up that the effect is sustained rather than transient. We secured a fully funded delivery collaboration with one of the most established names in LNP technology and broadened our intellectual property position. We enter the second half of the year with non-dilutive funding in place, an expanding partner dialogue in animal health, and further data readouts due on schedule."
SIRT6 PLATFORM: CLINICAL PROGRESS
Genflow's core scientific programme, the SIRT6 centenarian gene therapy, has generated a consistent body of positive data during the period.
SLAB Trial (Sarcopenia and Longevity in Aged Beagles)
Positive preliminary interim results reported in February: all treatment groups showed superior survival against the control group during the dosing period, with no adverse events observed and a favourable safety and tolerability profile across all four cohorts (24 beagle dogs aged over 10 years, two naked DNA dose levels, a single-dose AAV8 cohort, and control).
In April, follow-up observations taken three months after initial dosing confirmed the improvements had been maintained, with no adverse events recorded, providing early evidence of durability rather than a short-lived effect.
Methylation clock (biological age) analysis and muscle biopsy histology remain in progress. The trial is expected to conclude at the end of July 2026, with a comprehensive update on all remaining endpoints to follow.
Dog Aging Study (GF-1004
This separate, blinded trial, assessing sarcopenia, healthspan and lifespan-associated biomarkers over a 180-day monitoring period, is ongoing. A six-month efficacy assessment is expected in July 2026 to evaluate durability and longer-term effect.
PARTNERSHIPS AND NON-DILUTIVE FUNDING
Acuitas Therapeutics Collaboration (April 2026)
Genflow entered a strategic technology collaboration with Acuitas Therapeutics, a Vancouver-based specialist in lipid nanoparticle (LNP) delivery for mRNA therapeutics. Under the agreement, Genflow supplies its proprietary SIRT6 mRNA payload for Acuitas to formulate using its LNP platform, with the resulting formulations returned to Genflow for preclinical evaluation.
The collaboration is fully funded by Acuitas: there is no cash consideration payable by Genflow and the arrangement is entirely non-dilutive. The Company does not expect a material impact on near-term revenues but regards Acuitas' commitment of its own resources as third-party validation of the underlying science.
Animal Health Sector Engagement
Following the February SLAB interim results, Genflow expanded its confidentiality agreements with additional Tier-1 global animal health companies, broadening third-party evaluation of the canine SIRT6 data. These discussions remain exploratory, and the Company will update the market as appropriate.
Genflow has been invited to present SLAB study data at the Animal Longevity Summit in Toronto on 1-2 October 2026, alongside confirmed speakers including
speakers including American biologist and biogerontologist Dr Matt Kaeberlein best known for his research on evolutionarily conserved mechanisms of aging, Dr Vera Gorbunova, an endowed Professor of Biology at the University of Rochester and a co-director of the Rochester Aging Research Center and Dr Aubrey de Grey, an English biomedical gerontologist and the author of The Mitochondrial Free Radical Theory of Aging (1999) and co-author of Ending Aging (2007).
INTELLECTUAL PROPERTY
In April, Genflow's international PCT application, "Variants of Sirtuin 6 for the Treatment of Muscular Diseases" was published, extending patent coverage beyond longevity and metabolic applications into muscular disease indications including frailty syndrome and sarcopenia. This broadens the layered protection around the Company's SIRT6 platform and supports potential discussions with pharmaceutical and biotech partners across multiple jurisdictions.
PIPELINE: GLAUCOMA AND SARCOPENIA
The Company's glaucoma programme is prioritising delivery optimisation, with discussions ongoing with an LNP partner and selection underway of a contract research organisation for RNA-based formulation work through preclinical execution.
The broader sarcopenia programme continues to advance in line with our plans, supported by the ExoFastTrack initiative, which is intended to generate data supporting multiple programmes across the pipeline.
CORPORATE
Gad Berdugo joined the Board as Independent Non-Executive Chairman in January, bringing over 30 years of biotechnology leadership experience including prior roles as Chief Business Officer at Editas Medicine and Nutcracker Therapeutics. Tamara Joseph continues as a Director.
Mr Berdugo represented the Company at the BIO International Convention in San Diego in June, participating in a panel discussion on RNA therapeutics, and will present at the Animal Longevity Summit in October.
OUTLOOK
The Company expects a comprehensive update on remaining SLAB endpoints, including methylation clock and muscle histology data, following trial completion at the end of July. The GF-1004 six-month efficacy assessment is also due early H2 2026. Genflow's 2026 priorities remain pipeline discipline, capital efficiency and the pursuit of further non-dilutive collaboration agreements that provide external validation of the platform.
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
|
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire